Galectin Therapeutics says belapectin showed 15.9% placebo-adjusted improvement in predicted portal hypertension risk in MASH cirrhosis

Galectin Therapeutics says belapectin showed a 15.9% placebo-adjusted improvement in predicted portal hypertension risk in MASH cirrhosis, per analysis of the NAVIGATE trial.

Detected & updated continuously · Source: Nebula